Investigational drug · Phase 3
MenACYW conjugate vaccine
Also called: Nimenrix
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Healthy Volunteers, Meningococcal Immunisation, Meningococcal Immunization.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
1 still active
All registered trials
37
Any phase or sponsor naming "MenACYW conjugate vaccine"
First trial start
2023
Oct 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MenACYW conjugate vaccine", any sponsor or status.
- Phase 327
Conditions studied
As listed on its trial records.
- Healthy Volunteers
- Meningococcal Immunisation
- Meningococcal Immunization
- Meningococcal Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "MenACYW conjugate vaccine" as an intervention, largest first.
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07710872 · 4,568 participants (planned) · Start Aug 22, 2026 · Primary completion Mar 13, 2028
Drug: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA); Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) · For: Meningococcal Infection; Healthy Volunteers
Sites: Huanggang, China; Jianli City, Jingzhou City, China; Jingxi, China · 8 sites in all
- Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccinePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT02842853 · 3,344 participants · Start Jul 15, 2016 · Primary completion Feb 28, 2017
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine · For: Meningitis; Meningococcal Meningitis; Meningococcal Infections
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 89 sites in all
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT03673462 · 2,797 participants · Start Sep 17, 2018 · Primary completion Mar 16, 2023
Drug: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine); Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®) and 6 more · For: Healthy Volunteers (Meningococcal Infection)
Sites: Birmingham, Alabama; Dothan, Alabama; Phoenix, Arizona · 69 sites in all
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT03537508 · 2,627 participants · Start Apr 25, 2018 · Primary completion Sep 22, 2023
Drug: MenACYW conjugate vaccine; MenACYW-135 conjugate vaccine and 7 more · For: Healthy Volunteers (Meningococcal Infection)
Sites: Birmingham, Alabama; Dothan, Alabama; Phoenix, Arizona · 70 sites in all
- Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)Pivotal-lookingCompleted
Serum Institute of India Pvt. Ltd.Industry
NCT03964012 · 1,800 participants · Start Aug 20, 2019 · Primary completion Feb 23, 2020
Drug: NmCV-5; Menactra · For: Meningococcal Meningitis
Sites: Bamako, Mali; Fajara, The Gambia
- Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT02199691 · 1,715 participants · Start Jul 22, 2014 · Primary completion Oct 2, 2015
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine; Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine and 5 more · For: Meningitis; Meningococcal Meningitis; Meningococcal Infections
Sites: Birmingham, Alabama; Huntsville, Alabama; Downey, California · 36 sites in all
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT03547271 · 1,660 participants · Start Dec 14, 2018 · Primary completion May 17, 2023
Drug: MenACYW conjugate vaccine; Meningococcal group A, C, W-135, and Y conjugate vaccine and 4 more · For: Meningococcal Infections
Sites: Chlumec nad Cidlinou, Czechia; Domažlice, Czechia; Jindřichův Hradec, Czechia · 33 sites in all
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT07135986 · 1,602 participants · Start Sep 26, 2025 · Primary completion May 1, 2026
Drug: MenACYW conjugate vaccine; MenACYW135 polysaccharide vaccine and 1 more · For: Meningococcal Infection; Healthy Volunteers
Sites: Nanning, China; Jingxi, China; Liuzhou, China · 4 sites in all
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South AfricaPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT05794230 · 1,528 participants · Start Mar 27, 2023 · Primary completion Nov 15, 2025
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine and 13 more · For: Meningococcal Immunisation; Healthy Volunteers
Sites: Chennai, India; Hyderabad, India; Kanpur, India · 15 sites in all
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT04143061 · 1,328 participants · Start Dec 30, 2019 · Primary completion Jan 28, 2023
Drug: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine; Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine and 1 more · For: Meningococcal Immunization; Healthy Volunteers
Sites: Bangalore, India; Belagavi, India; Chennai, India · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Adult immunization.
· Med Lett Drugs Ther 2026
- Podcast: Immune Persistence After Primary Vaccination with MenQuadfi.
Rämet M, Simon M · Infect Dis Ther 2026
- Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.
Weisová P, Scheiblauer S, Ecker J, et al. · Nat Med 2026
- Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.
Martinon-Torres F, Lamberth E, Natalini Martinez S, et al. · Hum Vaccin Immunother 2025
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial.
Martinon-Torres F, Virta MM, Koski S, et al. · Infect Dis Ther 2025
- Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain.
Schley K, Findlow J, Molina C, et al. · Vaccines (Basel) 2025
Also in development for Healthy Volunteers
- PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease
- PCV21 vaccinePhase 35 trials
Sanofi · Pneumococcal Immunization, Healthy Volunteers
- TDVTAK-003, Tetravalent Dengue VaccinePhase 35 trials
Takeda · Dengue Fever, Healthy Volunteers
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- poliomyelitis vaccinePhase 33 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Whooping Cough, Diphtheria
- HexaximHexaxim Vaccine, DTaP-IPV-Hib-HepB vaccinePhase 32 trials
Sanofi · Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers
- IIV-HDstandalonePhase 32 trials
Sanofi · COVID-19 Immunization, Influenza Immunization, Immunization
- NVXC19EU licensed, standalonePhase 31 trial
Sanofi · Immunization, Healthy Volunteers, COVID-19 Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.